Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops

2017 ◽  
Vol 38 (3) ◽  
pp. 1193-1204 ◽  
Author(s):  
Ronald Mauricio Sanchez-Avila ◽  
Jesus Merayo-Lloves ◽  
Ana Cristina Riestra ◽  
Luis Fernandez-Vega Cueto ◽  
Eduardo Anitua ◽  
...  
Keyword(s):  
Growth Factors ◽  
Eye Drops ◽  
Neurotrophic Keratitis

scholarly journals Use of Plasma Rich in Growth Factors and ReGeneraTing Agent Matrix for the Treatment of Corneal Diseases

Vision ◽  
2021 ◽  
Vol 5 (3) ◽  
pp. 34
Author(s):  
Ronald M. Sánchez-Ávila ◽  
Edmar Uribe-Badillo ◽  
Carlos Fernández-Vega González ◽  
Francisco Muruzabal ◽  
Borja de la Sen-Corcuera ◽  
...  
Keyword(s):  
Growth Factors ◽  
Corneal Ulcer ◽  
Disease Index ◽  
Eye Drops ◽  
Analog Scale ◽  
Ocular Surface Disease Index ◽  
Corneal Ulcers ◽  
Corrected Visual Acuity ◽  
The Mean

This study aimed to investigate the use of Plasma Rich in Growth Factors (PRGF) associated with tissue ReGeneraTing Agent (RGTA) drops for the treatment of noninfectious corneal ulcers. RGTA treatment was applied (one drop every two days); however, if ulcer closure was not achieved, PRGF eye drops treatment was added (four times/day). The time taken to reach the ulcer closure, the Best Corrected Visual Acuity (BCVA), intraocular pressure (IOP), Visual Analog Scale (VAS, in terms of frequency and severity of symptoms), and Ocular Surface Disease Index (OSDI) were evaluated. Seventy-four patients (79 eyes) were included, and the mean age was 56.8 ± 17.3 years. The neurotrophic corneal ulcer was the most frequent disorder (n = 27, 34.2%), mainly for herpes virus (n = 15, 19.0%). The time of PRGF eye drops treatment associated with the RGTA matrix was 4.2 ± 2.2 (1.5–9.0) months, and the follow-up period was 44.9 ± 31.5 months. The ulcer closure was achieved in 76 eyes (96.2%). BCVA, VAS and OSDI improved from the baseline (p < 0.001), and IOP remained unchanged (p = 0.665). RGTA and PRGF in noninfectious ulcers were effective and could be a therapeutic alternative for this type of corneal disease.

scholarly journals Development and Optimization of Freeze-Dried Eye Drops Derived From Plasma Rich in Growth Factors Technology

2020 ◽  
Vol 9 (7) ◽  
pp. 35
Author(s):  
Eduardo Anitua ◽  
María de la Fuente ◽  
Ignacio Alcalde ◽  
Cristina Sanchez ◽  
Jesús Merayo-Lloves ◽  
...  
Keyword(s):  
Growth Factors ◽  
Eye Drops ◽  
Freeze Dried

Stability of freeze-dried plasma rich in growth factors eye drops stored for 3 months at different temperature conditions

2020 ◽  
pp. 112067212091303 ◽  
Author(s):  
Eduardo Anitua ◽  
María de la Fuente ◽  
Francisco Muruzábal ◽  
Jesús Merayo-Lloves
Keyword(s):  
Growth Factors ◽  
Room Temperature ◽  
Storage Condition ◽  
Eye Drops ◽  
Temperature Conditions ◽  
Healthy Donors ◽  
Freeze Dried ◽  
And Storage ◽  
Blood Centrifugation ◽  
Human Keratocytes

Purpose: The purpose of this study was to analyze the biological content and activity of freeze-dried plasma rich in growth factors eye drops after their storage at 4°C and at room temperature for 3 months with respect to fresh samples (time 0). Methods: Plasma rich in growth factors was obtained after blood centrifugation from three healthy donors. After platelet activation, the obtained plasma rich in growth factors eye drops were lyophilized alone or in combination with lyoprotectant (trehalose), then they were stored for 3 months at room temperature or at 4°C. Several growth factors were analyzed at each storage time and condition. Furthermore, the proliferative and migratory potential of freeze-dried plasma rich in growth factors eye drops kept for 3 months at different temperature conditions was evaluated on primary human keratocytes. Results: The different growth factors analyzed maintained their levels at each time and storage condition. Freeze-dried plasma rich in growth factors eye drops stored at room temperature or 4°C for 3 months showed no significant differences on the proliferative activity of keratocytes in comparison with fresh samples. However, the number of migratory human keratocytes increased significantly after treatment with lyophilized plasma rich in growth factors eye drops kept for 3 months compared to those obtained at time 0. No significant differences were observed between the freeze-dried plasma rich in growth factors eye drops whether mixed or not with lyoprotectant. Conclusion: Freeze-dried plasma rich in growth factors eye drops preserve the main growth factors and their biological activity after storage at room temperature or 4°C for up to 3 months. Lyophilized plasma rich in growth factors eye drops conserve their biological features even without the use of lyoprotectants for at least 3 months.

scholarly journals Treatment of Noninfectious Corneal Disorders With Plasma Rich in Growth Factors and ReGenerating Agent Matrix

2020 ◽  
Author(s):  
Ronald Mauricio Sanchez-Avila ◽  
Edmar Uribe-Badillo ◽  
Carlos Fernandez-Vega Gonzalez ◽  
Francisco Muruzabal ◽  
Borja De la Sen Corcuera ◽  
...  
Keyword(s):  
Growth Factors ◽  
Adverse Events ◽  
Corneal Ulcer ◽  
Eye Drops ◽  
Ocular Surface Disease Index ◽  
Corneal Ulcers ◽  
Corrected Visual Acuity ◽  
The Mean ◽  
Mean Time

Abstract Background: To provide the efficacy and safety of Plasma Rich in Growth Factors (PRGF) associated with tissue ReGeneraTing Agent (RGTA) drops for the treatment of noninfectious corneal ulcers.Methods: This retrospective study included patients from Fernandez-Vega University Institute between 2010 and 2019, with noninfectious corneal ulcers and no response to standard treatments. RGTA treatment was firstly applied (1 drop every two days), but if ulcer closure was not achieved, PRGF eye drops treatment was added (4 times/day). The time to reach the ulcer closure; the Best Corrected Visual Acuity (BCVA), intraocular pressure (IOP), Visual Analog Scale (VAS, in frequency and severity of symptoms), and Ocular Surface Disease Index (OSDI) were evaluated. The presence of adverse events along the follow-up period was also reported. Results: Seventy-four patients (79 eyes) were included in the study, forty-six eyes (62.2%) were women, and the mean age was 56.8 ± 17.3 years. The neurotrophic corneal ulcer was the most frequent disorder found in the patients of the study (n = 27, 34.2%), mainly due to the herpes virus (n = 15, 19.0%). The mean time of PRGF eye drops treatment associated with RGTA matrix was 4.2 ± 2.2 (1.5 -9.0) months, and the follow-up period was 44.9 ± 31.5 months. The ulcer closure was achieved in 76 eyes (96.2%). BCVA, VAS and OSDI improved significantly from the baseline (p<0.001), while IOP remained unchanged (p=0.665). No adverse events were recorded. Conclusions: The use of RGTA and PRGF in noninfectious ulcers was effective and safe, and it could be a therapeutic alternative for this type of corneal diseases.

Applications of Autologous Serum Eye Drops in Aniridic Keratopathy

2009 ◽  
Vol 03 (01) ◽  
pp. 51 ◽  
Author(s):  
José Santiago López-García ◽  
Keyword(s):  
Growth Factors ◽  
Tear Film ◽  
Biomechanical Properties ◽  
Autologous Serum ◽  
Eye Drops ◽  
Impression Cytology ◽  
Film Instability ◽  
Congenital Aniridia ◽  
Corneal Cells ◽  
Serum Eye Drops

Aniridia is an uncommon congenital bilateral disease that involves the cornea, anterior chamber, lens, retina and optic nerve. Corneal changes in aniridic keratopathy include recurrent erosions of corneal epithelium, tear film instability, chronic pain, corneal vascularisation, dry eye, progressive corneal opacification and blindness. The autologous serum contains a variety of growth factors, vitamins and immunoglobulins, some of which are in higher concentrations than in natural tears. The growth factors and protein found in the serum may help the proliferation, migration and adhesion of epithelial corneal cells. They are by nature non-allergenic and their biochemical and biomechanical properties are similar to those of normal tears. The ocular surface, including corneal impression cytology and tear film evaluation, of patients with congenital aniridia was studied prior to and after treatment with autologous serum eye drops.

scholarly journals Maxillary Zoster and Neurotrophic Keratitis following Trigeminal Block

2019 ◽  
Vol 10 (1) ◽  
pp. 61-66 ◽  
Author(s):  
Yang Kyung Cho ◽  
JinWoo Kwon ◽  
Sangeetha Pugazhendhi ◽  
Balamurali K. Ambati
Keyword(s):  
Herpes Zoster ◽  
Trigeminal Neuralgia ◽  
Nerve Block ◽  
Trigeminal Nerve ◽  
Viral Reactivation ◽  
Ocular Involvement ◽  
Eye Drops ◽  
Neurotrophic Keratitis ◽  
Trigeminal Block ◽  
Ophthalmic Branch

Herpes zoster ophthalmicus is commonly used to describe viral reactivation from the trigeminal ganglia with ocular involvement. The ophthalmic branch is the most commonly involved, whereas the maxillary and mandibular dermatomes are less commonly affected. Neurotrophic ulcer may occur secondary to intentional or inadvertent damage to the trigeminal nucleus, root, ganglion, or any segment of the ophthalmic branch of this cranial nerve. We report a case of reactivated maxillary herpes zoster combined with neurotrophic keratitis due to percutaneous 2nd and 3rd branch of trigeminal nerve block with alcohol to treat trigeminal neuralgia. A 57-year-old female came to the ophthalmology department complaining of decreased visual acuity and skin vesicle over the right lower lid and cheek. She had undergone right trigeminal nerve block for treatment of trigeminal neuralgia. Clinical examination revealed neurotrophic keratitis and maxillary herpes zoster. She was treated with oral and topical antivirals and vigorous lubrication with eye drops. Her neurotrophic keratitis showed a slow recovery. Although a few cases of herpes zoster following nerve block have been described, it would appear that a case of simultaneous maxillary herpes zoster and neurotrophic keratitis following trigeminal block has not yet been documented. It is possible that trigeminal nerve block may cause reactivation of latent virus and refractory neurotrophic keratitis.

scholarly journals Plasma rich in growth factors eye drops to treat secondary ocular surface disorders in patients with glaucoma

2018 ◽  
Vol Volume 11 ◽  
pp. 97-103 ◽  
Author(s):  
Ronald Mauricio Sanchez-Avila ◽  
Jesus Merayo-Lloves ◽  
Maria Laura Fernandez ◽  
Luis Alberto Rodríguez Gutiérrez ◽  
Pedro Pablo Rodríguez-Calvo ◽  
...  
Keyword(s):  
Growth Factors ◽  
Ocular Surface ◽  
Eye Drops

The Lucerne Protocol for the Production of Autologous Serum Eyedrops

2021 ◽  
Vol 238 (04) ◽  
pp. 346-348
Author(s):  
Frantisek Sanak ◽  
Philipp Baenninger ◽  
Claude Kaufmann ◽  
Katja Iselin ◽  
Lucas Bachmann ◽  
...  
Keyword(s):  
Growth Factors ◽  
Growth Factor ◽  
Room Temperature ◽  
Transforming Growth Factor ◽  
Serum Levels ◽  
Autologous Serum ◽  
Vertical Position ◽  
Eye Drops ◽  
Significant Difference ◽  
Serum Eye Drops

Abstract Background There are a variety of protocols for manufacturing autologous serum (AS) eye drops. The Lucerne protocol for the production of AS eye drops uses a slightly reduced gravitational (g)-force and time for the centrifugation process (2500 × g for 10 minutes), compared to previously published optimised protocols, to obtain high levels of epitheliotropic growth factors (3000 × g for 15 minutes). The goal of this study was to compare the concentrations of growth factors, albumin and lysozyme in autologous serum eye drops manufactured with these protocols. Material and Methods Blood from 5 healthy volunteers was placed in plastic tubes without an anticoagulant. Tubes from each donor were left in a vertical position for 2 hours at room temperature to facilitate coagulation, followed by centrifugation at either 2500 × g for 10 minutes or at 3000 × g for 15 minutes at room temperature. The serum levels of beta nerve growth factor (β-NGF), transforming growth factor β1 (TGF-β1), epidermal growth factor (EGF), hepatocyte growth factor (HGF), platelet-derived growth factor BB (PDGF-BB) and vascular endothelial growth factor A (VEGF-A) were measured in triplicate with a multi-analyte Simple Plex platform. The Simple Plex cartridge allows each sample to be run in triplicate for each analyte and prevents any interaction between the antibody components for each biomarker. The serum level of albumin was measured by turbidimetric immunoassay Tina-quant and of lysozyme by single radial immunodiffusion assay. Results For all analytes, the reduced g-force and centrifugation time did not result in a significant difference in serum levels. Conclusions The Lucerne protocol for the production of autologous serum eye drops with reduced g-force and a shorter centrifugation time does not affect the concentrations of the main epitheliotropic growth factors, albumin and lysozyme, in AS eye drops.

Sign in / Sign up

Export Citation Format

Share Document